Last Update 20 Mar 26

BCRX: Astria Acquisition And FY26 Outlook Will Support Long Term Upside

Analysts lifted their price targets on BioCryst to a range of $17 to $22, citing steady FY26 guidance, reaffirmed peak revenue goals, and confidence in the Astria Therapeutics acquisition and BCX17725 data timeline as key supports for the higher valuations.

Analyst Commentary

Recent Street research on BioCryst highlights a mix of optimism around the Astria Therapeutics acquisition, reaffirmed FY26 guidance, and the commercial trajectory of Orladeyo, alongside growing interest in the BCX17725 program as a potential long term driver. Price targets in the latest notes span a range from $17 to $22, reflecting different views on execution, competitive risks, and how much value to ascribe to the pipeline and integration of Astria assets.

Positive analysts point to the company reiterating its FY26 outlook and peak revenue goals after closing the Astria deal. They view this as a sign that management is comfortable with both the commercial franchise and the updated development roadmap. Some also highlight the potential for meaningful contribution from navenibart and other acquired programs over time, in addition to Orladeyo and BCX17725, as a key reason for maintaining constructive views on the stock.

Other coverage focuses on specific product level assumptions. In one case, Orladeyo is modeled to reach a peak of US$900m in sales by 2029, with navenibart viewed as having the potential to reach US$1b in risk adjusted sales. These kinds of forecasts help frame how much of the current valuation may already reflect expectations for the existing commercial business compared with the earlier stage pipeline and integration upside from Astria.

At the upper end of the recent range, a US$22 price target sits modestly above the prior US$21 figure, supported by steady guidance and the view that BCX17725 data timing into year end 2026 is tracking as planned. Supportive analysts generally argue that the commercial execution to date and reaffirmed long term goals justify staying constructive, while acknowledging that much of the value investors ascribe to BioCryst still depends on consistent delivery over several years.

For retail investors, the key takeaway is that Street views, even when broadly positive, rest heavily on a set of assumptions around peak sales, successful integration of Astria, and the eventual readout of later stage programs. Price targets provide a reference point for how these views are being translated into numbers, but they also underline where expectations could be tested by slower adoption, pipeline setbacks, or changes to the competitive backdrop.

Bearish Takeaways

Bearish analysts may question whether current price targets in the US$17 to US$22 range already assume smooth execution on both Astria integration and existing commercial plans. This could limit upside if progress is more gradual than expected.
Some caution is likely around the ambitious product level assumptions, such as Orladeyo modeling at US$900m and navenibart at US$1b in risk adjusted sales. These targets could be difficult to achieve if competition increases, pricing pressure builds, or market expansion slows.
BCX17725 data are tracking toward year end 2026, and bearish analysts may highlight the long wait for new readouts as a risk, since any delay or underwhelming data could pressure valuation that already bakes in meaningful pipeline contribution.
Reaffirmed FY26 guidance and peak revenue goals are supportive, but more cautious voices may argue that investors have limited visibility into the integration of Astria assets. This leaves room for execution hiccups that could weigh on both growth expectations and the stock’s risk profile.

What's in the News

The company entered a new loan agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. for term loans with gross proceeds of US$400m, to be issued in multiple tranches, with a maturity date of January 23, 2031 (Key Developments).
The loan carries quarterly interest-only payments until maturity, with principal due at the maturity date, and allows up to 200 basis points of interest to be paid in kind and added to principal during the first two years (Key Developments).
Interest on the term loans is set at the three-month SOFR rate, with a floor of 1.75%, plus 4.50% per year, and an additional 0.50% interest margin in periods when payment-in-kind interest is used (Key Developments).
The company issued full-year 2026 earnings guidance, with total revenue expected in a range of US$635m to US$660m (Key Developments).

Valuation Changes

Fair Value: Stays unchanged at $13.0, indicating no revision to the central valuation estimate.
Discount Rate: Reduced slightly from 7.85% to 7.42%, which lowers the required return used in the valuation work.
Revenue Growth: Shifted from an 11.57% growth assumption to a 1.18% decline, marking a significant reset in top line expectations.
Net Profit Margin: Cut from 8.44% to 4.04%, implying a more conservative view on future profitability.
Future P/E: Raised sharply from 49.9x to 145.1x, suggesting that a larger share of the valuation now rests on earnings further out in time or on lower near term earnings assumptions.

2 views

Key Takeaways

Heavy reliance on a single product exposes BioCryst to risks from competition, regulatory shifts, and a limited pipeline in the rare disease market.
Expanding demand for innovative rare disease therapies could be offset by rising pricing pressures, regulatory hurdles, and competition from larger and emerging market players.
Overdependence on a single product, limited pipeline, rising competition, and regulatory pressures threaten future revenue growth, profitability, and margin sustainability.

Catalysts

About BioCryst Pharmaceuticals

A biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.What are the underlying business or industry changes driving this perspective?

While BioCryst has experienced outstanding quarterly revenue growth driven by strong demand for ORLADEYO, expansion of new patient prescriptions, and improved gross-to-net performance, the long-term sustainability of revenue remains vulnerable due to the company's reliance on a single product and the ever-present risk of competition in the rare disease space.
Although the addressable market for rare and genetic diseases is expanding globally thanks to demographic trends and shifting patient/physician preferences toward more convenient oral therapies, BioCryst faces ongoing regulatory and pricing pressures in the U.S. and abroad, which could cap revenue growth and compress net margins over time.
While increasing healthcare spending and insurance coverage have supported greater access to innovative drugs like ORLADEYO, rising political and public resistance to high drug prices, along with potential challenges in payer reimbursement policy, could drive future pricing constraints and limit operating margin expansion.
Despite management's emphasis on building a pipeline and deploying cash from operational strength and divestitures into new rare disease assets, clinical and regulatory risk remains high due to a relatively thin late-stage pipeline-failures or delays in advancing new therapies could undermine future earnings growth.
While longer regulatory exclusivity and incentives for orphan drug development are intended to benefit rare disease-focused companies, intensifying competition from large pharmaceutical firms and emerging gene therapy modalities increases the risk of share erosion and may ultimately pressure BioCryst's long-term revenue and earnings trajectory.

BioCryst Pharmaceuticals Earnings and Revenue Growth

BioCryst Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on BioCryst Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming BioCryst Pharmaceuticals's revenue will decrease by 1.2% annually over the next 3 years.
The bearish analysts assume that profit margins will shrink from 30.2% today to 4.0% in 3 years time.
The bearish analysts expect earnings to reach $34.1 million (and earnings per share of $0.11) by about March 2029, down from $263.9 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $155.5 million.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 145.3x on those 2029 earnings, up from 9.3x today. This future PE is greater than the current PE for the US Biotechs industry at 15.4x.
The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.42%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

BioCryst's heavy reliance on a single product, ORLADEYO, for 90% of its revenue poses significant concentration risk, and increased competition or adverse clinical events could materially decrease future revenues and earnings.
The company's pipeline remains thin, with two assets (for Netherton syndrome and DME) still in early clinical stages and no clear pathway to accelerated approval or regulatory clarity, raising concerns about the timing and probability of new revenue streams to offset ORLADEYO dependency, thereby threatening long-term revenue growth and future earnings visibility.
Intensifying competition in hereditary angioedema, including recent launches like garadacimab and Ekterly, as well as potential future oral and gene therapies, could erode ORLADEYO's market share and limit pricing power, thereby putting downward pressure on both revenue and net margins over time.
Broader industry trends such as increasing regulatory scrutiny, payer pressures, and shifting healthcare models toward value-based care may limit the company's ability to sustain high prices for niche therapies, potentially capping revenue growth and squeezing operating margins in the long run.
Strategic plans for inorganic growth and asset acquisitions are dependent on continued strong cash generation and could be hampered if market conditions change or if BioCryst overpays or fails to integrate new assets, putting both cash flow and future profitability at risk.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for BioCryst Pharmaceuticals is $13.0, which represents up to two standard deviations below the consensus price target of $21.3. This valuation is based on what can be assumed as the expectations of BioCryst Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $32.0, and the most bearish reporting a price target of just $13.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $844.3 million, earnings will come to $34.1 million, and it would be trading on a PE ratio of 145.3x, assuming you use a discount rate of 7.4%.
Given the current share price of $9.81, the analyst price target of $13.0 is 24.5% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on BioCryst Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Rare Disease Focus Will Face Intense Rivalry Yet Value Persists